This is the authors' abstract. We don't add key points for this paper.
] Specifically, plasma cells and mature B lymphocytes targeted by BCMA CAR T cells are also integral components of the humoral immune system. However, the prevalence and clinical significance of APBs in patients with MM after CAR T-cell therapy remain unclear.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: